|
|
 |
| Epigenomics AG Reports First Half 2010 Results |
Tuesday, 10.08.2010 |
|
Key Figures
- Revenue: EUR 1.0 million in H1 2010 (H1 2009: EUR 2.1 million)
- EBIT: EUR -5.4 million in H1 2010 (H1 2009: EUR -4.8 million)
- Net loss: EUR 5.4 million in H1 2010 (H1 2009: EUR 4.8 million)
- Liquid assets: EUR 32.3 million as of 30/06/2010 (31/12/2009: EUR 6.1 million)
Highlights of the First Half 2010 and year to date
- Financial position improved significantly
- Broadened availability of Epi proColon product in Europe
- ARUP launches Septin9 testing for colorectal cancer in the U.S.A.
- Septin9 colorectal cancer biomarker patent granted in the U.S.A.
- Licensed Septin9 non-exclusively to Canadian Warnex Medical Laboratories
- Presented final prospective PRESEPT colorectal cancer clinical study data at leading conference
- Demonstrated 81% sensitivity at 95% specificity for SHOX2 lung cancer biomarker in EU pivotal clinical study
- Launched Epi proLung BL Reflex Assay in Europe
Press release, Berlin, Germany, and Seattle, WA, U.S.A., |
|
| Epigenomics AG: Licensee ARUP Launches Septin9 Colorectal Cancer Blood Test in the United States |
Wednesday, 21.07.2010 |
|
| Press release Berlin and Seattle, July 21, 2010 |
|
| Ad Hoc Announcement pursuant to para 15 WpHG (German Securities Trading Act) |
Tuesday, 20.07.2010 |
|
| Epigenomics AG: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United States |
|
| Epigenomics AG Launches Diagnostic Lung Cancer Test in Europe |
Wednesday, 07.07.2010 |
|
The Epi proLung BL Reflex Assay complements conventional diagnostic methods
Test may identify cancers otherwise missed
Epigenomics’ second molecular diagnostic product launched in Europe
Commercial potential from direct sales as well as licensing and partnering going forward
Press release, Berlin, Germany, and Seattle, WA, USA |
|
| Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial |
Wednesday, 23.06.2010 |
|
Epi proLung BL Reflex Assay demonstrates outstanding technical and clinical performance in pivotal IVD performance evaluation study
Novel test introduced to leading pathologists and Oncologists
CE-marking and launch as IVD test expected within the next few weeks
Press release, Berlin, Germany, and Seattle, WA, USA |
|
| Epigenomics AG: Partnership with Laboratory Network MDI – A Successful Model for Introducing Blood-based Colorectal Cancer Early Detection |
Thursday, 17.06.2010 |
|
Innovative Septin9 blood-test offers new opportunities in colorectal cancer early detection
Efficient partnerships between laboratories and Epigenomics in educating physicians and patients
Survey shows high level of awareness and acceptance of Septin9 testing among primary care physicians
Press release, Berlin, Germany, and Seattle, WA, USA |
|
| Epigenomics AG Reports First Quarter 2010 Financial Results |
Tuesday, 11.05.2010 |
|
Key Figures
- Revenue: EUR 0.62 million in Q1 2010 (Q1 2009: EUR 1.24 million)
- EBIT: EUR -2.61 million in Q1 2010 (Q1 2009: EUR -2.31 million)
- Net loss: EUR -2.59 million in Q1 2010 (Q1 2009: EUR -2.42 million)
- Liquid assets: Strengthened balance sheet by financing transaction
Highlights of the First Quarter 2010
- Successfully completed prospective PRESEPT colorectal cancer clinical study, presentation of results at Digestive Disease Week
- Capital Increase secures funding
- Key financials according to plan
- Broadened availability of Epi proColon product in Germany and Switzerland
- Received Notice of Allowance for patent in Japan for HeavyMethyl™ technology
- Introduced Epi proLung BL Reflex Assay at major congress in Germany
Press release, Berlin, Germany, and Seattle, WA, USA, |
|
| PRESEPT Study Results Sponsored by Epigenomics AG Presented at Digestive Disease Week |
Wednesday, 05.05.2010 |
|
mSEPT9 biomarker successfully validated as the first biomarker in blood capable of detecting previously unsuspected colorectal cancers in prospective colorectal cancer screening study
Final data to be submitted for publication in top-tier journal
The CE marked Epi proColon assay, based on mSEPT9, provides attractive and convenient alternative for colorectal cancer screening
Berlin, Germany, and Seattle, WA, USA, |
|
| Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test Screening to Canadian Warnex Medical Laboratories |
Monday, 03.05.2010 |
|
Warnex to offer a laboratory-developed blood testing service based on Epigenomics’ Septin9 Biomarker
Press release, Berlin, Germany, and Laval, QC, Canada |
|
| Epigenomics AG Receives Allowance of Key Patent in the U.S |
Tuesday, 27.04.2010 |
|
Patent covers detection of colorectal cancer with Septin9 Biomarker
Press release, Berlin, Germany, and Seattle, WA, USA, |
|
| Epigenomics Reports on a Successful Year 2009 at Annual Press Conference and Analyst Meeting |
Monday, 19.04.2010 |
|
Key financials improved significantly in 2009
Important development and commercialization milestones met in 2009
Expect revenue growth and similar earnings in 2010
|
|
| Epigenomics AG sponsors Felix Burda Award 2010 |
Monday, 19.04.2010 |
|
Company for the first time supported prestigious award for achievement in colorectal cancer screening
Epigenomics’ Septin9 blood test for colorectal cancer early detection available in Germany since October 2009
Research study aimed at enhancing blood test to detect precursor lesions nominated for the award
|
|
| Epigenomics AG: Laboratory Network synlab Now Offering Septin9 Testing |
Wednesday, 07.04.2010 |
|
European diagnostic laboratory network synlab has started offering Septin9 blood testing through its 55 German sites
synlab to measure Septin9 using Epi proColon kit on Applied Biosystems 7500 Fast Real-time PCR System; CE-marked kit now also validated for this instrument
Berlin, Germany, and Seattle, WA, USA |
|
| Epigenomics AG: Financial Results for the Fiscal Year 2009 |
Friday, 12.03.2010 |
|
Press release, Berlin, Germany, and Seattle, WA, U.S.A., March 12, 2010
|
|
| Epigenomics AG Receives Allowance for Key Technology Patent in Japan |
Thursday, 11.03.2010 |
|
Patent broadly covers HeavyMethyl, a core technology of Epigenomics’ molecular diagnostic products
Press release, Berlin, Germany, and Seattle, WA, USA, March 11, 2010 |
|
| Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG: PRESEPT Academic Research Study Meets Its Primary Objective |
Monday, 08.03.2010 |
|
|
|
| Epigenomics AG Introduces New Lung Cancer Test at German Cancer Congress |
Wednesday, 24.02.2010 |
|
New IVD test expected to be launched in Q2 2010
Test supports accurate diagnosis of lung cancer in suspicious cases
Conference presentations on scientific evidence and clinical utility
Press release, Berlin, Germany, and Seattle, WA, U.S.A., |
|
| Epigenomics AG: Blood Test for Colorectal Cancer Now Available Nationwide in Germany and Switzerland |
Tuesday, 23.02.2010 |
|
Colorectal cancer test Epi proColon now available nationwide in Germany and Switzerland four months after product launch
Epigenomics to present recent clinical data at 29th German Cancer Congress (Deutscher Krebskongress) in Berlin, Germany
Press release, Berlin, Germany, and Seattle, WA, U.S.A., |
|
| Epigenomics AG Reports Conclusions from PRESEPT Study Audit |
Thursday, 04.02.2010 |
|
- Differences in analytical instrument read-out requires verification and potential retesting of samples measured in laboratory with deviating results
- Top-line data expected still in Q1 2010
- No impact on commercial strategy expected
Press release, Berlin, Germany, and Seattle, WA, U.S.A. |
|
| Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG Releases Preliminary PRESEPT Study Data |
Friday, 15.01.2010 |
|
|
|
| Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S. |
Monday, 11.01.2010 |
|
|
|
top of the page
|
